Miyatsuka T, Matsuoka TA, Kaneto H. Transcription factors as therapeutic targets for diabetes.
Expert Opin Ther Targets 2009;
12:1431-42. [PMID:
18851698 DOI:
10.1517/14728222.12.11.1431]
[Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND
Islet cell implantation and pancreas transplantation have been used as treatments for diabetes but are limited by the shortage of donors and the requirement for lifelong immunosuppression. As an alternative, the generation of surrogate insulin-producing cells has been an area of interest for many researchers. Understanding how pancreatic beta-cells are generated during pancreas development will provide information that can be applied to generating surrogate beta-cells.
OBJECTIVE
To outline the current knowledge of pancreas development and differentiation, with a focus on the regulatory network of pancreas-enriched transcription factors and their targets.
METHODS
A review of relevant literature.
CONCLUSIONS
Pancreatic and duodenal homeobox 1 (Pdx1), Neurogenin 3 (Ngn3), and musculoaponeurotic fibrosarcoma oncogene homolog A (MafA) have been shown to play essential roles in pancreas development and beta-cell differentiation, and gain-of-function approaches indicate the potency of these factors for inducing differentiation of non-beta-cells into insulin-producing cells, which could lead to a novel therapy to cure diabetes.
Collapse